Bortezomib in multiple Myeloma: A practice guideline

Clinical Oncology

Volumn 26, Issue 2, 2014, Pages 110-119

  Kouroukis, C T ^a   Baldassarre, F G ^b   Haynes, A E ^b   Imrie, K ^c   Reece, D E ^c   Cheung, M C ^d  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Bortezomib; Multiple myeloma; Practice guideline; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; PLACEBO;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANADA; CANCER SURVIVAL; COCHRANE LIBRARY; CONSENSUS DEVELOPMENT; CONSUMER; CYTOPENIA; DISEASE CONTROL; EMBASE; HERPES ZOSTER; HUMAN; MEDLINE; META ANALYSIS; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION PROCESS; VIRUS REACTIVATION;

BORTEZOMIB; MULTIPLE MYELOMA; PRACTICE GUIDELINE; PROTEASOME INHIBITORS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PYRAZINES;

EID: 84892481567     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.11.022     Document Type: Article

References (33)

1. Yang H., Zonder J.A., Dou Q.P. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 2009, 18:957-971.
2. Reece D., Imrie K., Stevens A., Smith C.A. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. Curr Oncol 2006, 13:162-172.
3. Anonymous Bortezomib approved in Canada as first-line treatment of multiple myeloma 2008, Doctor's guide.
4. Engelhardt M., Kleber M., Udi J., et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010, 51:1424-1443.
5. NCCN clinical practice guidelines in oncology (NCCN Guidelines™): multiple myeloma 2011, National Comprehensive Cancer Network.
6. Palumbo A., Sezer O., Kyle R., et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23:1716-1730.
7. Browman G.P., Levine M.N., Mohide E.A., et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. JClin Oncol 1995, 13:502-512. Comment in: Ann Oncol 2002;13(9):1507-1509; author reply: 1509.
8. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEngl J Med 2008, 359:906-917.
9. San Miguel J.F., Schlag R., Khuageva N.K., et al. Updated follow-upand results of subsequent therapy in the phase III VISTAtrial:bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 2008, 112:A650.
10. Mateos M.-V., Richardson P.G., Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. JClin Oncol 2010, 28:2259-2266.
11. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. JClin Oncol 2010, 28:5101-5109.
12. Mateos M.-V., Oriol A., Martinez-Lopez J., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11:934-941.
13. Kumar S., Flinn I., Richardson P.G., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119:4375-4382.
14. Niesvizky R., Flinn I.W., Rifkin R., et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood 2011, 118:478.
15. Harousseau J.-L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. JClin Oncol 2010, 28:4621-4629.
16. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
17. Sharma M., Khan H., Thall P.F., et al. Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012, 118:2507-2515.
18. Moreau P., Avet-Loiseau H., Facon T., et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011, 118:5752-5758. quiz 5982.
19. Rosinol L., Cibeira M.T., Mateos M.V., et al. Aphase III PETHEMA/GEM randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow Transplant 2012, 47. S2.
20. Sonneveld P., Schmidt-Wolf I.G.H., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30:2946-2955.
21. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med 2005, 352:2487-2498.
22. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
23. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. JClin Oncol 2007, 25:3892-3901.
24. Lonial S., Kaufman J., Tighiouart M., et al. Aphase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010, 16(20):5079-5086.
25. Reece D.E., Sullivan D., Lonial S., et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011, 67:57-67.
26. Hjorth M., Hjertner O., Knudsen L.M., et al. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol 2012, 88:485-496.
27. Garderet L., Iacobelli S., Moreau P., et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European group for blood and marrow transplantation. JClin Oncol 2012, 30:2475-2482.
28. Orlowski R.Z., Gercheva L., Williams C., et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. JClin Oncol 2012, 30:8018.
29. Chanan-Khan A., Sonneveld P., Schuster M.W., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. JClin Oncol 2008, 26:4784-4790.
30. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440. Erratum Lancet Oncol 2011;12(6):522.
31. Richardson P.G., Sonneveld P., Schuster M.W., et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007, 137:429-435.
32. San-Miguel J.F., Richardson P.G., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
33. Sonneveld P., Hajek R., Nagler A., et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112:1529-1537.